The Biomembrane Institute

Other

University of Washington

Ann Stapleton

Edward D Nudelman

Walter E Stamm

Sen-Itiroh Hakomori

Sen-itiroh Hakomori

Mark R Stroud

Compositions and methods for diagnosing, treating and preventing recurrent urinary tract infections relate to the detection and use of globosides, such as disialosyl galactosyl-globoside (DSGG) and sialosyl galactosyl-globoside (SGG), and stabilized forms thereof, such as those wherein sialic acid is replaced by KDN

Compositions for treating Escherichia coli urinary tract infections

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le.sup.a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le.sup.a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue.

Method for determining susceptibility to Escherichia coli urinary tract

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E. coli bacterial receptor or bacterial receptor analogue are disclosed.

Method for determining susceptibility to escherichia coli urinary tract

Growing community of inventors

Seattle, WA, United States of America

Ann Stapleton